Harm Reduction Group Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Harm Reduction Group.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Tobacco earnings growth | 20.7% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Harm Reduction Group AB (publ)'s (NGM:NOHARM) Shares Leap 26% Yet They're Still Not Telling The Full Story
Jun 22Is Harm Reduction Group (NGM:NOHARM) Using Debt In A Risky Way?
May 29Harm Reduction Group AB (publ) (NGM:NOHARM) Might Not Be As Mispriced As It Looks After Plunging 25%
Apr 24Market Cool On Harm Reduction Group AB (publ)'s (NGM:NOHARM) Revenues Pushing Shares 30% Lower
Mar 05Health Check: How Prudently Does Harm Reduction Group (NGM:NOHARM) Use Debt?
Feb 29Further Upside For Harm Reduction Group AB (publ) (NGM:NOHARM) Shares Could Introduce Price Risks After 32% Bounce
Jan 05It's Down 28% But Harm Reduction Group AB (NGM:NOHARM) Could Be Riskier Than It Looks
Sep 05Does Harm Reduction Group (NGM:NOHARM) Have A Healthy Balance Sheet?
Sep 01Companies Like SealWacs (NGM:SEAL) Are In A Position To Invest In Growth
Dec 28In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Harm Reduction Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2024 | 167 | -27 | -4 | -4 | N/A |
12/31/2023 | 169 | -27 | 5 | 5 | N/A |
9/30/2023 | 174 | -21 | 47 | 9 | N/A |
6/30/2023 | 177 | -21 | 29 | -5 | N/A |
3/31/2023 | 180 | -14 | -22 | -21 | N/A |
12/31/2022 | 178 | -11 | -17 | -15 | N/A |
9/30/2022 | 154 | -11 | -83 | -44 | N/A |
6/30/2022 | 122 | -11 | -63 | -28 | N/A |
3/31/2022 | 118 | -12 | -4 | -4 | N/A |
12/31/2021 | 80 | -11 | -15 | -15 | N/A |
9/30/2021 | 29 | -8 | -9 | -9 | N/A |
6/30/2021 | 25 | -5 | -7 | -7 | N/A |
3/31/2021 | N/A | -2 | -1 | -1 | N/A |
12/31/2020 | N/A | -2 | -1 | -1 | N/A |
9/30/2020 | 28 | 0 | 3 | 3 | N/A |
6/30/2020 | 15 | 0 | 3 | 3 | N/A |
3/31/2020 | N/A | -1 | -1 | -1 | N/A |
12/31/2019 | N/A | -1 | -1 | -1 | N/A |
9/30/2019 | N/A | -2 | -2 | -2 | N/A |
6/30/2019 | N/A | -2 | -2 | -2 | N/A |
3/31/2019 | N/A | -3 | -3 | -3 | N/A |
12/31/2018 | N/A | -3 | -2 | -2 | N/A |
9/30/2018 | N/A | -2 | -2 | -2 | N/A |
6/30/2018 | N/A | -2 | -2 | -2 | N/A |
3/31/2018 | N/A | -2 | -2 | -2 | N/A |
12/31/2017 | N/A | -2 | N/A | -3 | N/A |
9/30/2017 | N/A | -3 | N/A | -2 | N/A |
6/30/2017 | N/A | -3 | N/A | -3 | N/A |
3/31/2017 | N/A | -3 | N/A | -3 | N/A |
12/31/2016 | N/A | -3 | N/A | -2 | N/A |
9/30/2016 | N/A | -2 | N/A | -2 | N/A |
6/30/2016 | N/A | -2 | N/A | -2 | N/A |
3/31/2016 | N/A | -2 | N/A | -2 | N/A |
12/31/2015 | N/A | -2 | N/A | -1 | N/A |
9/30/2015 | N/A | -1 | N/A | -1 | N/A |
6/30/2015 | N/A | -1 | N/A | -1 | N/A |
3/31/2015 | N/A | -1 | N/A | -1 | N/A |
12/31/2014 | N/A | 0 | N/A | 0 | N/A |
9/30/2014 | N/A | 0 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if NOHARM's forecast earnings growth is above the savings rate (1.1%).
Earnings vs Market: Insufficient data to determine if NOHARM's earnings are forecast to grow faster than the Swedish market
High Growth Earnings: Insufficient data to determine if NOHARM's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if NOHARM's revenue is forecast to grow faster than the Swedish market.
High Growth Revenue: Insufficient data to determine if NOHARM's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NOHARM's Return on Equity is forecast to be high in 3 years time